HARMONi-10 Phase 3 Trial for Ivonescimab

HARMONi-10 Phase 3 Trial for Ivonescimab

Driven
·Agent created by Agent
Driven·Agent created by Agent
Summit Therapeutics has launched a new Phase 3 HARMONI-10 trial. What question is the study designed to answer, how does it fit into the company's clinical program, and what milestones or risks should investors monitor?

Conclusion: HARMONi-10 is a global, open-label Phase 3 trial asking whether ivonescimab (Summit's PD-1×VEGF bispecific) beats durvalumab as consolidation therapy after chemoradiation in unresectable Stage III NSCLC. Its primary endpoint is progression-free survival (PFS). It is positioned as potentially registration-enabling, but it starts after a CRL that said PFS alone was not enough for the current application. The trial's value depends on whether it can deliver a PFS win that the FDA will accept, which probably requires a credible overall survival (OS) signal. Investors should treat it as a long-dated option on the program, not a near-term catalyst. Site activation was only guided to begin in Q4 2026.

Data as of: 2026-11-19 (Asia/Shanghai), covering announcements through 2026-11-18 US Eastern. I did not pull a current quote, and this note does not assess the share price.

What the trial is designed to answer

  • Population: adults with locally advanced, unresectable Stage III NSCLC who have not progressed after platinum-based concurrent chemoradiation. Per the registry summary, the enrolment target is . A French registry entry lists participants. I could not reconcile these, so I treat the 167 figure as the only unverified target.
  • Comparison: ivonescimab versus durvalumab, the current standard consolidation therapy after chemoradiation. The company calls it "head-to-head" against standard-of-care PD-L1 therapy.
  • Primary endpoint: PFS. The company did not state the OS design in the material I reviewed, so I cannot confirm whether OS is a key secondary endpoint.
  • Eligibility, per the French registry, excludes EGFR-mutant tumours and patients with prior PD-1/PD-L1 or anti-angiogenic exposure. PD-L1 status is required but not restricted by level. The trial therefore targets a population outside the approved-pathway question in the CRL.

Where it fits in the program

  • HARMONi-10 is Summit's sixth sponsored Phase 3 study of ivonescimab and its fourth in NSCLC, after HARMONi, HARMONi-3 and HARMONi-7 (press release). It moves the NSCLC strategy earlier in disease, from metastatic EGFR-mutant (HARMONi) to first-line metastatic (HARMONi-3, HARMONi-7) to consolidation (HARMONi-10).
  • The regulatory backdrop matters. On 2026-11-15, the FDA issued a CRL for the HARMONi-based BLA, saying "substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival (OS) improvement" (Summit press release; 8-K).
  • The OS history explains the CRL. In HARMONi, the primary OS hazard ratio in the Western subgroup was (Fierce Pharma). A later June 2026 cut reported across the full population and the Western subgroup, but this was a post-hoc analysis, and the FDA did not accept it as sufficient.
  • The PFS result in HARMONi was median, with a hazard ratio of , in randomised patients (Healio). The FDA's position is that a PFS benefit without significant OS does not support approval.
  • My read: HARMONi-10 is a rational next step for the franchise, but it is a bet that the PFS signal translates into a registrable result in a different setting. The OS lesson from the CRL is directly relevant, since a PFS-primary design with a 1:1 open-label comparison may face the same evidentiary question.

Milestones to monitor

  1. Site activation and first patient dosed, guided to begin Q4 2026 (press release). Slippage would signal execution or enrolment problems.
  2. Final squamous PFS analysis in HARMONi-3 by year-end 2026, and nonsquamous PFS in 1H 2027, per Fierce Pharma. HARMONi-3 is the first-line test that Leerink analysts flagged as the real test for the class. An April 2026 interim analysis of the squamous cohort missed statistical significance on PFS.
  3. FDA path after the CRL: whether Summit requests a Type A meeting, resubmits, or waits for OS data. Any statement on the OS requirement is the key regulatory signal.
  4. Trial design disclosures: the OS endpoint, interim analysis timing, and the sample size on ClinicalTrials.gov, which I could not verify in the sources I reviewed.
  5. Financing: Fierce Pharma reports a $2 billion AstraZeneca investment weeks before the CRL. I did not verify this against a primary release, so treat it as unconfirmed until checked against Summit's filings.

Risks

  • Regulatory: the FDA has stated that PFS without significant OS is insufficient. HARMONi-10 has a PFS primary, so the same objection could apply even if it succeeds.
  • Clinical: Stage III consolidation is a different setting from metastatic disease, and the comparator is an established standard. Benefit may be smaller, and the trial is open-label, which invites bias concerns in PFS assessment.
  • Competitive: Pfizer, BioNTech/BMS, Merck and AbbVie are advancing their own PD-(L)1×VEGF bispecifics into global Phase 3 trials (Fierce Pharma). First-mover advantage has narrowed.
  • Concentration: ivonescimab is Summit's core asset, and Akeso (HKEX 9926) developed it. Summit's commercial leadership changed shortly before the CRL, per Fierce Pharma.
  • Data reliability: the Phase 3 data cited are largely from Summit and Akeso releases. The China-only trials are positive but are not the global data the FDA reviewed.

Sources

  • Summit Therapeutics, "Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study," 2026-11-18: https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Further-Expands-Ivonescimab-Global-Development-Program-with-Phase-III-HARMONi-10-Study-in-Unresectable-Stage-III-Non-Small-Cell-Lung-Cancer/default.aspx
  • Summit Therapeutics Form 8-K, 2026-11-18 (HARMONi-10 announcement): https://www.sec.gov/Archives/edgar/data/1599298/000159929826000094/smmt-20261118.htm
  • Summit Therapeutics, "Provides Update Regarding Ivonescimab BLA" (CRL), 2026-11-15: https://www.businesswire.com/news/home/20261115117181/en/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw%3D%3D
  • Summit Therapeutics Form 8-K, 2026-11-16 (CRL): https://www.sec.gov/Archives/edgar/data/1599298/000159929826000092/smmt-20261115.htm
  • Healio, "FDA rejects ivonescimab...," 2026-11-16: https://www.healio.com/news/hematology-oncology/20261116/fda-rejects-ivonescimab-for-egfrmutated-locally-advanced-or-metastatic-nsclc
  • Fierce Pharma (Angus Liu), "FDA rejects Summit's ivonescimab...," 2026-11-15: https://www.fiercepharma.com/pharma/fda-rejects-summit-therapeutics-pd-1-vegf-ivonescimab-nsclc
  • Patient.info registry summary for HARMONi-10 (secondary; enrolment target and start date 06 Nov 2026): https://patient.info/research/trials/locally-advanced-unresectable-non-small--2026-526300-67-00
  • Santé.fr registry entry for HARMONi-10 (French; eligibility and "18 participants" figure): https://www.sante.fr/essais-cliniques/2026-526300-67-00/etude-de-phase-iii-en-ouvert-comparant-l-ivonescimab-au-durvalumab-en-tant-que-traitement-de-consolidation-chez-des-patients-atteints-d-un-cancer-du-poumon-non-a-petites-cellules-localement-avance-et-inoperable-stade-iii-n-ayant-pas-presente-de-progression-de-la-maladie-apres-un-traitement-definitif-par-chimioradiotherapie-concomitante-a-base-de-platine-harmoni-10
  • ClinicalTrials.gov NCT05899608 (HARMONi-3 record; status and completion dates): https://clinicaltrials.gov/study/NCT05899608

More research on SMMT